In this Section |
263618 Characteristics of breast cancer by molecular subtypes among a Hispanic PopulationMonday, October 29, 2012
Breast cancer (BC) is the leading cause of cancer death among females in Puerto Rico (PR). It is a heterogeneous disease with distinct molecular subtypes based on gene expressions patterns. We aimed to assess the differences in breast cancer by molecular subtypes (BCMS) in PR. A case-case analysis was conducted using invasive BC cases consulted to the UPR-School of Medicine Immunoperoxidase Laboratory from 2008-2010. BCMS were characterized in 172 tumor specimens based on immunohistochemical surrogates for ER, PR and HER-2 status. The BCMS were defined as: luminal (ER+ and/or PR+), non-luminal (ER-, PR-). Logistic regression was used to evaluate risk factors differences between breast cancer cases by molecular subtypes. The luminal subtype was the most prevalent in our sample (75.0%) compared with the non-luminal (25.0%) subtype. Unadjusted association with BC risk factors differed by tumor subtypes. Compared to non-luminal subtype, luminal subtype cases are less likely to have older age at menopause (OR: 0.26, 95% CI: 0.08, 0.82), to be overweight or obese (OR: 0.89, 95% CI: 0.40, 1.94) and to have higher tumor histological grade (OR: 0.42, 95% CI: 0.18, 0.97). Even though this is a small pilot study, it is very suggestive of important risk factors differences for luminal breast cancer subtype. Future studies to further assess the association between BC risk factors and BCMS will add to the biologic understanding of BC.
Learning Areas:
EpidemiologyLearning Objectives: Keywords: Cancer, Epidemiology
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: I am a Masters in Science of Epidemiology student who have been involved in several research projects focusing on the epidemiology of breast cancer and chronic diseases. Among my scientific interests my primary goal is to conduct research focusing on cancer disparities among Hispanics populations, considering that these populations suffer disproportionally from the burden of cancer. I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
Back to: 3299.0: Epidemiology & Biostatistics for Health Solutions
|